AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (currently amended) A pharmaceutical composition comprising an active pharmaceutical ingredient which exists in a first polymorph form susceptible to ~~degradation or~~ interconversion into one or more other polymorph forms, and further comprising from about 50 % to about 70 % by weight silicified microcrystalline cellulose, a stabilizing substance selected from the group consisting of colloidal silicon dioxide, finely divided silicon dioxide, ~~silicified microcrystalline cellulose,~~ magnesium oxide, calcium oxide, and polyethylene glycol ~~and croscarmellose sodium~~, and optionally one or more pharmaceutically acceptable excipients, wherein the stabilizing substance is present in an amount from 1 % to about 10 % by weight of the pharmaceutical composition.

Claim 2. (original) A pharmaceutical composition according to claim 1, wherein said active pharmaceutical ingredient is the potassium salt of losartan.

Claim 3. (original) A pharmaceutical composition according to claim 2 wherein the potassium salt of losartan is in the amorphous form.

Claim 4. (original) A pharmaceutical composition according to claim 2 wherein the potassium salt of losartan is in the polymorph form exhibiting its strongest diffractions in a powder X-ray diffractogram at around 2θ=6.9, 13.8, 20.6, 24.0, 24.8, 28.7 and 29.2°.

Claim 5. (previously presented) A pharmaceutical composition according to claim 1 which is in the form of a coated tablet.

Claim 6. (previously presented) A pharmaceutical composition according to claim 5 characterized in that it is coated with a film coating comprising stearic acid or ethylcellulose in an amount of from about 0.1% to about 1.7% by weight of the pharmaceutical composition.

Claim 7. (previously presented) A pharmaceutical composition according to claim 1 wherein said stabilizing substance is finely divided anhydrous silicon dioxide or polyethylene glycol present in amount of 1% to about 10% by weight of the composition.

Claim 8. (previously presented) A pharmaceutical composition according to claim 7 which is a finished dosage form comprising from 1 % to about 10% by weight of the composition of finely divided silicon dioxide.

Claim 9. (previously presented) A pharmaceutical composition according to claim 8 wherein said finely divided silicon dioxide is Syloid™ silicon dioxide.

Claim 10. (previously presented) A pharmaceutical composition according to claim 9 comprising from about 3% to about 10% by weight of the composition of Syloid™ silicon dioxide.

Claim 11-17. (canceled)

Claim 18. (currently amended) A method for treating hypertension and/or chronic renal failure comprising administering to a patient in need thereof a pharmaceutical composition comprising

an active pharmaceutical ingredient which exists in a first polymorph form susceptible to ~~degradation or~~ interconversion into one or more other polymorph forms, and further comprising from about 50 % to about 70 % by weight silicified microcrystalline cellulose, a stabilizing substance selected from the group consisting of colloidal silicon dioxide, finely divided silicon dioxide, ~~silicified microcrystalline cellulose,~~ magnesium oxide, calcium oxide, and polyethylene glycol ~~and croscarmellose sodium~~, and optionally one or more pharmaceutically acceptable excipients, wherein the stabilizing substance is present in an amount from 1 % to about 10 % by weight of the pharmaceutical composition.

Claim 19. (previously presented) The method according to claim 18 wherein the active pharmaceutical ingredient is a potassium salt of losartan.